Atara biotherapeutics, inc. (ATRA)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'12
Operating activities
Net loss

-298,228

-290,976

-292,492

-278,958

-255,513

-230,699

-186,000

-158,735

-135,280

-119,491

-102,413

-96,690

-88,142

-79,049

-82,062

-68,557

-64,622

-57,221

-46,500

-40,551

-30,117

-28,006

0

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense

52,071

51,696

49,175

46,274

39,072

33,817

30,361

27,110

24,767

23,100

18,659

17,927

17,407

16,784

18,092

15,058

12,492

10,251

13,060

11,310

9,267

10,101

0

0

0

0

Depreciation and amortization expense

7,400

7,100

6,600

6,000

4,967

3,700

2,622

1,672

1,127

1,000

851

732

574

383

237

116

57

48

23

15

11

6

0

0

0

-

Amortization (accretion) of investment premiums (discounts)

830

1,330

1,723

1,946

2,126

1,885

1,214

483

-214

-732

-378

-747

-1,597

-2,582

-4,562

-4,879

-4,393

-3,465

0

0

0

-

-

-

-

-

Non-cash operating lease expense

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash interest expense

-

-

-

-

-

211

211

125

64

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Asset retirement obligation accretion expense

73

71

70

68

66

49

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

In-process research and development acquired from Amgen

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Loss on foreign exchange

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

Investment premium amortization, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

Interest accrued on notes receivable from stockholder

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2

0

0

0

-

Changes in operating assets and liabilities:
Prepaid expenses and other current assets

1,452

998

2,221

3,083

7,009

5,764

1,998

2,020

1,172

784

1,265

651

-761

742

-1,145

-1,731

990

767

3,793

4,296

2,371

1,246

0

0

0

0

Operating lease assets

-

-

-

-

-

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other assets

-75

-322

-219

-43

436

314

225

26

-880

-2

-2

75

730

-6

5

30

12

61

53

62

69

37

0

0

0

0

Accounts payable

951

4,213

-547

898

2,833

-1,958

2,280

1,703

510

2,163

-2,038

-556

64

981

2,610

1,633

1,102

1,005

1,286

1,027

-231

-164

0

0

0

0

Accrued compensation

2,217

4,070

3,825

2,546

3,147

4,972

3,753

2,014

1,703

1,919

2,163

1,127

1,272

1,121

1,594

1,211

815

1,399

1,062

565

323

894

0

0

0

0

Accrued research and development expenses

1,633

-10,869

2,369

-1,522

-142

15,204

-7

4,590

4,230

1,598

-1,299

-1,728

-2,324

-2,704

2,572

-1,525

2,696

4,288

0

0

0

-

-

-

-

-

Other current liabilities

2,009

-394

-1,408

-1,712

-625

2,491

2,855

4,281

2,261

1,896

886

140

-275

215

463

-2,719

733

293

-173

2,896

-324

4

0

0

0

0

Operating lease liabilities

-623

-731

-487

-299

-261

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other long-term liabilities

-

-

-

-

-

372

129

410

450

407

348

-50

270

398

424

513

154

29

0

0

0

-

-

-

-

-

Income tax payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

Net cash used in operating activities

-232,470

-235,626

-234,355

-230,305

-215,150

-179,772

-147,291

-119,423

-100,290

-87,502

-83,728

-79,081

-69,568

-60,025

-50,253

-47,571

-43,025

-37,156

-30,721

-21,913

-20,333

-16,628

0

0

0

0

Purchases of short-term investments

319,654

270,230

211,055

126,431

181,449

466,489

426,243

421,711

416,938

176,459

205,486

231,317

225,953

304,928

346,665

454,457

455,943

379,776

0

0

0

-

-

0

0

-

Sales of short-term investments

-

-

-

-

-

-

-

-

116,061

-

113,352

199,112

194,233

242,643

0

0

0

-

-

-

-

-

-

-

-

-

Maturities of short-term investments

-

-

-

-

-

-

-

-

151,681

-

183,391

146,075

145,957

149,046

0

0

0

-

-

-

-

-

-

-

-

-

Proceeds from maturities and sales of short-term investments

357,599

336,261

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

Purchases of property and equipment

6,270

5,733

7,190

10,202

16,913

35,925

41,453

43,148

38,834

20,232

11,530

5,722

3,335

3,020

2,296

1,924

1,176

290

55

46

50

46

0

0

0

0

Net cash provided by investing activities

31,836

60,459

105,400

175,354

121,224

-196,289

-199,387

-204,209

-188,030

99,909

79,727

108,148

110,902

83,741

41,534

-146,389

-195,833

-220,127

-257,643

-106,192

-74,381

-83,363

0

0

0

0

Financing activities
Proceeds from sale of common stock in underwritten offerings, net

-

-

-

-

-

293,290

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock through ATM facilities, net

72,006

47,729

0

0

0

-

-

-

-

19,156

0

0

0

-

-

-

-

-

0

0

0

-

-

-

-

0

Proceeds from employee stock awards

5,933

7,350

11,022

14,510

21,252

24,691

19,282

15,611

7,435

1,249

845

1,066

586

600

0

0

0

-

-

-

-

-

-

-

-

-

Taxes paid related to net share settlement of restricted stock units

3,515

6,695

6,705

10,742

8,714

7,503

7,499

3,447

3,395

357

370

382

388

94

0

0

0

-

-

-

-

-

-

-

-

-

Principal payments on finance lease obligations

478

486

477

491

525

528

396

272

101

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Other financing activities, net

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Repayment of notes receivable from stockholder

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

337

0

0

0

-

Proceeds from sale of convertible preferred stock, net of offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

13,481

0

0

0

0

Net cash provided by (used in) financing activities

214,669

188,786

157,358

10,907

59,599

357,536

352,213

362,598

316,385

20,048

19,681

10,010

198

506

360

194,225

189,721

259,226

317,127

122,515

126,289

70,273

0

0

0

0

Proceeds from sale of unvested restricted stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Offering costs incurred

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Effect of exchange rates on cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

Decrease in cash, cash equivalents and restricted cash

14,035

13,619

28,403

-44,044

-34,327

-18,525

5,535

38,966

28,065

32,455

15,680

39,081

41,574

24,222

-8,453

167

-49,273

1,849

28,763

-5,590

31,575

-29,718

0

0

0

0

Non-cash investing and financing activities
Property and equipment purchases included in accounts payable and other accrued liabilities

708

276

-1,695

-3,026

-1,860

1,579

11,031

12,698

14,020

10,122

3,287

2,351

559

352

0

0

0

-

-

-

-

-

-

-

-

-

Finance lease assets obtained in exchange for lease obligations

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued costs related to ATM facilities

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Receivable for options exercised

0

-

-

0

0

-

-

0

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Capitalized lease obligations

-

-

-

-

-

441

0

0

0

-

-

-

286

-

0

0

0

-

-

-

-

-

-

-

-

-

Asset retirement costs

-

-

-

-

-

88

668

668

668

580

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest capitalized during construction period for build-to-suit lease arrangement

-

-

-

-

-

77

208

246

341

264

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Issuance of Series A-1 convertible preferred stock to Amgen in exchange for license

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Change in obligation to issue Series A-1 convertible preferred stock to Amgen

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Issuance of common stock upon vesting of stock awards

-

-

-

-

-

-

-

-

-

-

-

-

-

60

80

80

80

80

85

85

90

90

0

0

0

-

Change in long-term liabilities related to non-vested stock awards

-

-

-

-

-

-

-

-

-

-

-

-

-

-60

-80

-80

-80

-80

-85

-85

-90

-90

0

0

0

-

Supplemental cash flow disclosure
Cash paid for interest

67

50

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash paid for income taxes

0

-

-

-

0

-

-

-

-

-

-

-

9

10

11

4

4

3

2

2

2

70

0

0

0

0

Offering costs in anticipation of initial public filing included in other accrued liabilities and accounts payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-